goldennet

JUN.24
2022

Genomics Shareholders' Meeting Approves NT$0.2 Stock Dividend and Election of Director

國內基因定序領導大廠基龍米克斯生物科技股份有限公司(以下簡稱「基米」,股票代碼:4195)今(24)日召開2022年股東常會,會中承認2021年度營業報告書、財務報表與盈餘分配案,並通過以資本公積配發每股0.2元股票股利。股東會也通過修訂公司章程與股東會議事規則,並補選一席董事,由台安生物科技總經理林世嘉當選。

基龍米克斯去年合併營收3.9億元,歸屬母公司稅後淨利18,738千元,每股稅後盈餘(EPS)為0.32元。董事長周孟賢感謝董事及所有股東的支持,並表示去年受新冠肺炎影響與調整發展策略,營收表現雖不如預期,但仍繳出獲利成績單,而為開創公司成長新動能與提升永續經營價值,藉由在科研服務領域紮下厚實的競爭力,重新從需求端切入找出未被滿足的商機,並採借力使力的結盟策略擴大營運能量。


展望未來,總經理江俊奇表示,目前有多項具體合作案持續推動,對公司長期營運發展正向樂觀。包括與全球次世代基因定序大廠Illumina針對「液態活檢」(Liquid Biopsy)共同發展癌症藥物的基因檢測服務,盼推廣成為新一代用藥指引或復發監控,以及與工研院合作興建全台第一座PIC/S GMP等級的商用核酸及多肽工廠,預計今年10月取得ISO認證,並有望於第四季正式量產,現階段已開始與潛在客戶洽談量產訂單。


江俊奇進一步指出,核酸是許多生技產品的原料,包括核酸藥、疫苗佐劑、PCR檢測探針等都是衍伸產品。過去商用核酸皆仰賴進口,新冠肺炎大流行曝露出本土供應鏈的缺口,基龍米克斯原本就是台灣實驗室用核酸的最大供應商,在工研院協助下進行技術與設備升級,發展商業與臨床應用核酸市場,對基龍米克斯來說,不僅是朝具高研發能量CDMO(委託開發暨製造服務)營運模式升級的重大里程碑,更是完成國內核酸與疫苗產業鏈的關鍵拼圖,建構完整的供應鏈體系,搶攻全球商機。


今年前5月基龍米克斯的合併營收為1.64億元,年增7.45%,重返成長軌道,主要受惠新冠病毒檢測產品銷售大幅增加所帶動。基龍米克斯表示,新冠病毒檢測產品已列為常規品項銷售,而隨著科研服務市場需求回溫,客戶訂單持續擴增,加上GMP核酸廠投產後對營收帶來的潛在貢獻,預期下半年營運將優於上半年。

Other News

Other News

Kaohsiung Veterans General Hospital Departmental Seminar: Progress and Prospects in Precision Medicine

Kaohsiung Veterans General Hospital Department of Medical Research Seminar: Progress and Prospects in Precision Medicine Date: July 8 (Friday) at 8:30AM Location: Kaohsiung Veterans General Hospital Department of Medical Research Speaker: Dr. Chen Chien Wen, Director of the Advanced Technology Development Division

JUL.04
2022

Genomics Teams Up with NTU Biotech Center to Establish a Forward-Looking Technology Industry-Academia Collaboration and Education Platform for Win-Win Cooperation

Genomics Bioscience & Technology Co. Ltd., a leading domestic company in genetic sequencing (referred to as “Genomics”, stock code: 4195), signed a “Memorandum of Understanding for Forward-Looking Technology Industry-Academia Collaboration and Education Platform” with NTU Biotechnology Center (referred to as “NTU Biotech Center”) today (14th). Both parties will jointly establish a core laboratory and create a forward-looking biotechnology practical field within the NTU campus. They will also organize a series of applied courses, allowing students to embrace the latest biotechnology techniques, align with industry development trends, and foster outstanding local biotechnology talents through industry-academia collaboration. This initiative aims to strengthen Taiwan's innovative research and development capabilities in biotechnology, enhancing the competitiveness and status of Taiwan's biotechnology industry in the international market.

APR.14
2022

Top

Contact

Contact Us

Contact

Contact Us

Search

Search Entire Website

Search for products or news